


Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Journals	Bo		
Search	PubMed	▼ for					Go	Clear		
		<input checked="" type="checkbox"/> Limits	Preview/Index	History	Clipboard	Details				
Display		Abstract	▼	Show: 20	▼	Sort	▼	Send to	Text	▼

☐ 1: Oncogene. 1999 Apr 1; 18(13): 2241-51.

[Related Articles, Links](#)

Entrez PubMed



Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.

PubMed Services

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinar F, Slamon D.

Division of Hematology-Oncology, UCLA School of Medicine, Los Angeles, California 90095, USA.

Related Resources

Previous studies have demonstrated a synergistic interaction between rhuMab HER2 and the cytotoxic drug cisplatin in human breast and ovarian cancer cells. To define the nature of the interaction between rhuMab HER2 and other classes of cytotoxic drugs, we applied multiple drug effect/combination index (CI) isobologram analysis to a variety of chemotherapeutic drug/rhuMab HER2 combinations in vitro. Synergistic interactions at clinically relevant drug concentrations were observed for rhuMab HER2 in combination with cisplatin (CI=0.48, P=0.003), thiotepa (CI=0.67, P=0.0008), and etoposide (CI=0.54, P=0.0003). Additive cytotoxic effects were observed with rhuMab HER2 plus doxorubicin (CI=1.16, P=0.13), paclitaxel (CI=0.91, P=0.21), methotrexate (CI=1.15, P=0.28), and vinblastine (CI=1.09, P=0.26). One drug, 5-fluorouracil, was found to be antagonistic with rhuMab HER2 in vitro (CI=2.87, P=0.0001). In vivo drug/rhuMab HER2 studies were conducted with HER-2/neu-transfected, MCF7 human breast cancer xenografts in athymic mice. Combinations of rhuMab HER2 plus cyclophosphamide, doxorubicin, paclitaxel, methotrexate, etoposide, and vinblastine in vivo resulted in a significant reduction in xenograft volume compared to chemotherapy alone (P<0.05). Xenografts treated with rhuMab HER2 plus 5-fluorouracil were not significantly different from 5-fluorouracil alone controls consistent with the subadditive effects observed with this combination in vitro. The synergistic interaction of rhuMab HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are

rational combinations to test in human clinical trials.

PMID: 10327070 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Show:	20	▼	Sort	▼	Send to	Text	▼
---------	----------	---	-------	----	---	------	---	---------	------	---

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

Jan 20 2004 07:12:30

0



Gateway

your entrance to the
knowledge resources of the
National Library of Medicine

New Search

[Overview](#)[What's New](#)[Help](#)[FAQ](#)[Other NLM
Resources](#)[Ordering Info.](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[HSTAT](#)[LOCATORplus](#)[MEDLINEplus](#)[PubMed](#)[TOXNET](#)

Concept Details

Paclitaxel

A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.

[Related
Concepts](#)[View MeSH
Information](#)[Add to
Search](#)

using Connector:

AND

or

[Cancel](#)

- ☐ Main point of item
☐ Do not explode this term

With Subheadings:

[Subheading
Definitions](#)

- | | |
|---|---|
| <input type="checkbox"/> administration & dosage | <input type="checkbox"/> economics |
| <input type="checkbox"/> adverse effects | <input type="checkbox"/> history |
| <input type="checkbox"/> agonists | <input type="checkbox"/> immunology |
| <input type="checkbox"/> analogs & derivatives | <input type="checkbox"/> isolation & purification |
| <input type="checkbox"/> analysis | <input type="checkbox"/> metabolism |
| <input type="checkbox"/> antagonists & inhibitors | <input type="checkbox"/> pharmacokinetics |
| <input type="checkbox"/> biosynthesis | <input type="checkbox"/> pharmacology |
| <input type="checkbox"/> blood | <input type="checkbox"/> poisoning |
| <input type="checkbox"/> cerebrospinal fluid | <input type="checkbox"/> radiation effects |
| <input type="checkbox"/> chemical synthesis | <input type="checkbox"/> standards |
| <input type="checkbox"/> chemistry | <input type="checkbox"/> supply & distribution |
| <input type="checkbox"/> classification | <input type="checkbox"/> therapeutic use |
| <input type="checkbox"/> contraindications | <input type="checkbox"/> toxicity |
| <input type="checkbox"/> diagnostic use | <input type="checkbox"/> urine |

MeSH Tree 1

- ▶ All MeSH Categories
 - ▶ Chemicals and Drugs (MeSH Category)
 - ▶ Organic Chemicals
 - ▶ Hydrocarbons
 - ▶ Terpenes
 - ▶ Diterpenes
 - ▶ Taxoids
 - ▼ **Paclitaxel**

MeSH Tree 2

- ▶ All MeSH Categories
 - ▶ Chemicals and Drugs (MeSH Category)
 - ▶ Organic Chemicals
 - ▶ Hydrocarbons
 - ▶ Hydrocarbons, Cyclic
 - ▶ Hydrocarbons, Alicyclic
 - ▶ Cycloparaffins
 - ▶ Cyclodecanes
 - ▶ Taxoids
 - ▼ **Paclitaxel**

Contact Us

U.S. National Library of Medicine | National Institutes of Health | Department of Health & Human Services | Copyright | Privacy |
Accessibility | Freedom of Information Act